ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$5.99▲ +0.84%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Phathom Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Phathom Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Phathom Pharmaceuticals a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $4.98 and $6.81; in 9 out of 10, between $3.77 and $8.98. Estimated annual volatility is 95%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $560M
- 52-week high
- $18.31
- 52-week low
- $5.01
- Revenue (12 months)
- $240M
- Revenue growth (YoY)
- +216.9%
- Gross margin
- 87.1%
- Operating margin
- -91.4%
- Net margin
- -126.3%
- Return on equity
- 50.5%
- Free cash flow (12 months)
- $-32.6M
- Beta
- 0.51
What this means
ATLAS does not publish a fair value for PHAT right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks PHAT has traded between $5.01 and $18.31. Today it is 67.3% below that high and 20% above its low.
On the business: revenue grew 216.9% year over year; net margin is 126.3%.
Its beta is 0.51: it tends to move less than the market.
About the company
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases.
Want to see everything about Phathom Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases.
What is the chance PHAT goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, PHAT ends the month between $4.98 and $6.81.
How big is Phathom Pharmaceuticals and what is its P/E ratio?
Phathom Pharmaceuticals's market capitalization is $560M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is PHAT?
ATLAS estimates annual volatility at 95%. In a typical month, half of the outcomes end between $4.98 and $6.81.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer